Every material Form 8-K Aclaris Therapeutics, Inc. has filed with the SEC since October 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Aclaris Therapeutics reported third-quarter 2026 results on November 5, 2026, with a net loss of $18.5 million, up from $14.6 million a year earlier, and total revenue of $1.5 million, down from $3.3 million. The company said the revenue decline was mainly due to a sales milestone under the Sun Pharma license agreement recorded in the 2025 periods, while research and development spending rose on the ATI-052 program. Cash, cash equivalents and marketable securities were $204.6 million at September 30, 2026, and the company said this, plus an October 2026 offering, should fund operations through the first half of 2029.
Q3 2026 net loss was $18.5 million versus $14.6 million in Q3 2025; nine-month net loss was $59.8 million versus $45.1 million.
Q3 2026 total revenue was $1.5 million versus $3.3 million; nine-month revenue was $5.1 million versus $6.5 million.
Q3 2026 R&D expenses were $16.1 million versus $13.0 million, driven mainly by ATI-052 costs.
October 2026 offering raised $50.0 million in aggregate gross proceeds; company expects cash to last through the first half of 2029.
On October 27, 2026, Aclaris Therapeutics entered an underwriting agreement to sell 7,785,714 shares of common stock at $3.50 each, plus pre-funded warrants for 6,500,000 shares, in an offering under an effective Form S-3 registration. The Company estimates net proceeds of about $46.7 million, with closing expected on October 28, 2026. Because the offering adds new shares and warrants, existing shareholders' ownership percentage could be diluted.
7,785,714 common shares offered at $3.50 per share
Pre-funded warrants for 6,500,000 shares priced at $3.49999 each, with a $0.00001 exercise price
Estimated net proceeds of about $46.7 million; closing expected October 28, 2026
Underwriters include Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co.
Aclaris Therapeutics reported primary analysis results from two small Phase 1b proof-of-concept trials of its bispecific antibody ATI-052, in atopic dermatitis (14 patients) and asthma (16 patients). The company also estimated unaudited cash, cash equivalents and marketable securities of approximately $204.6 million as of September 30, 2026, and said it will prioritize development in eosinophilic esophagitis with a Phase 2b trial planned for early 2027.
Atopic dermatitis trial: 45% placebo-adjusted mean EASI improvement at day 57, from a per-protocol population of nine active-arm and one placebo-arm patient
Asthma trial: 59% mean FeNO reduction at day 15 in the ATI-052 arm versus 15% in the placebo arm, with 16 patients enrolled
Estimated cash, cash equivalents and marketable securities of approximately $204.6 million as of September 30, 2026; figure is unaudited and may change
Company plans to start a Phase 2b trial in eosinophilic esophagitis in early 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Aclaris Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →